Biofrontera Inc. (BFRI)
BFRI Stock Price Chart
Explore Biofrontera Inc. interactive price chart. Choose custom timeframes to analyze BFRI price movements and trends.
BFRI Company Profile
Discover essential business fundamentals and corporate details for Biofrontera Inc. (BFRI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
29 Oct 2021
Employees
92.00
Website
https://www.biofrontera.us.comCEO
Hermann Luebbert
Description
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
BFRI Financial Timeline
Browse a chronological timeline of Biofrontera Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 19 Mar 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is -$0.40, while revenue estimate is $9.00M.
Earnings released on 13 Aug 2025
EPS came in at -$0.57 falling short of the estimated -$0.45 by -26.67%, while revenue for the quarter reached $9.03M , missing expectations by -5.45%.
Earnings released on 15 May 2025
EPS came in at -$0.47 falling short of the estimated -$0.14 by -235.71%, while revenue for the quarter reached $8.59M , missing expectations by -18.60%.
Earnings released on 21 Mar 2025
EPS came in at -$2.33 falling short of the estimated $0.02 by -11.75K%, while revenue for the quarter reached $12.55M , beating expectations by +19.53%.
Earnings released on 13 Nov 2024
EPS came in at -$0.86 falling short of the estimated -$0.73 by -17.81%, while revenue for the quarter reached $9.01M , missing expectations by -9.97%.
Earnings released on 14 Aug 2024
EPS came in at -$1.12 surpassing the estimated -$1.19 by +5.88%, while revenue for the quarter reached $7.84M , missing expectations by -4.52%.
Earnings released on 15 May 2024
EPS came in at -$1.85 falling short of the estimated -$1.63 by -13.50%, while revenue for the quarter reached $7.90M , missing expectations by -27.25%.
Earnings released on 15 Mar 2024
EPS came in at -$2.33 falling short of the estimated -$1.19 by -95.80%, while revenue for the quarter reached $10.60M , missing expectations by -10.28%.
Earnings released on 9 Nov 2023
EPS came in at -$4.64 falling short of the estimated -$4.23 by -9.69%, while revenue for the quarter reached $8.88M , missing expectations by -28.63%.
Earnings released on 11 Aug 2023
EPS came in at -$6.14 falling short of the estimated -$5.14 by -19.46%, while revenue for the quarter reached $5.85M , missing expectations by -5.68%.
Stock split effective on 5 Jul 2023
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 May 2023
EPS came in at -$4.40 matching the estimated -$4.40, while revenue for the quarter reached $8.73M , missing expectations by -4.56%.
Earnings released on 13 Mar 2023
EPS came in at -$2.80 falling short of the estimated -$2.60 by -7.69%, while revenue for the quarter reached $10.14M , beating expectations by +44.30%.
Earnings released on 14 Nov 2022
EPS came in at -$4.60 surpassing the estimated -$6.40 by +28.13%, while revenue for the quarter reached $4.32M , missing expectations by -52.77%.
Earnings released on 12 Aug 2022
EPS came in at -$8.80 falling short of the estimated -$6.20 by -41.94%, while revenue for the quarter reached $4.46M , missing expectations by -2.04%.
Earnings released on 13 May 2022
EPS came in at -$1.60 surpassing the estimated -$2.80 by +42.86%, while revenue for the quarter reached $9.75M , missing expectations by -0.82%.
Earnings released on 8 Apr 2022
EPS came in at -$8.40 falling short of the estimated -$3.60 by -133.33%, while revenue for the quarter reached $9.17M , missing expectations by -0.75%.
Earnings released on 30 Nov 2021
EPS came in at -$10.20 surpassing the estimated -$11.60 by +12.07%, while revenue for the quarter reached $4.33M , missing expectations by -10.77%.
Earnings released on 1 Nov 2021
EPS came in at -$0.01 , while revenue for the quarter reached $5.86M .
Earnings released on 31 Mar 2021
EPS came in at -$0.01 , while revenue for the quarter reached $4.74M .
Earnings released on 31 Dec 2020
EPS came in at -$0.00 , while revenue for the quarter reached $8.57M .
Earnings released on 30 Sept 2020
EPS came in at -$0.01 , while revenue for the quarter reached $3.25M .
BFRI Stock Performance
Access detailed BFRI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.